http://rdf.ncbi.nlm.nih.gov/pubchem/patent/MX-2012008475-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71aef749d5bc9c4735952ba45002e88f |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1652 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2846 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-265 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N47-06 |
| filingDate | 2011-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3fb1aca007c681be92c189e3522e27f |
| publicationDate | 2013-11-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | MX-2012008475-A |
| titleOfInvention | FORMULATION OF MODIFIED RELEASE AND METHODS FOR USE. |
| abstract | A modified-release pharmaceutical formulation contains approximately 30-70% N- (2-amino-4- (fluorobenzylamino) -phenyl) carbamic acid (retigabine) ethyl ester, or a salt, solvate or hydrate accepted for pharmaceutical use thereof. , approximately 5-30% of a matrix for delivery of the drug containing hydroxypropyl methylcellulose (HPMC) and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine after administration to an individual for 4-20 hours longer than the time required for an in vitro release of 80% reagentine. The plasma concentration profile against time of this formulation is practically flat for a prolonged period that lasts approximately 4 hours to approximately 36 hours. One method of treating a disorder characterized by hyperexcitability of the nervous system is to administer to an individual an effective amount of these pharmaceutical formulations. |
| priorityDate | 2010-01-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 27.